Prescient Therapeutics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PSTTF research report →
About the company
Operating from Melbourne, Australia, Prescient Therapeutics Limited is a clinical-stage oncology company dedicated to pioneering novel pharmaceutical treatments for a variety of cancers. The company's primary investigational therapy, PTX-200, is currently undergoing several advanced clinical trials: a Phase 2a study for HER2-negative breast cancer, a Phase 1B/2 trial addressing relapsed and refractory acute myeloid leukemia (AML), and a Phase 1b trial for platinum-resistant ovarian cancer that has recurred or persisted. Another key pipeline asset is PTX-100, a RhoA inhibitor, engineered to combat both blood and solid tumors, particularly those characterized by specific Ras and RhoA genetic mutations.
- CEO
- Steven Lee Yatomi-Clarke
- IPO
- 2017
- HQ
- Melbourne, VIC, AU
Price Chart
- Market Cap
- $117.53M
- P/E
- -6.73
- P/S
- 23.01
- P/B
- 4.02
- EV/EBITDA
- -6.18
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -323.82%
- Net Margin
- -285.08%
- ROE
- -62.49%
- ROIC
- -33.53%
- 52W High
- $0.14
- 52W Low
- $0.02
- 50D MA
- $0.06
- 200D MA
- $0.05
- Beta
- 1.04
- Avg Volume
- 0
Get TickerSpark's AI analysis on PSTTF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our PSTTF coverage
Recent articles, reports, and earnings notes.
No research on PSTTF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PSTTF report →Similar companies
Peers in the same neighborhood.